Your browser is no longer supported. Please, upgrade your browser.
Settings
PSDV pSivida Corp. daily Stock Chart
PSDV [NASD]
pSivida Corp.
Index- P/E- EPS (ttm)-0.55 Insider Own16.10% Shs Outstand33.44M Perf Week1.14%
Market Cap59.52M Forward P/E- EPS next Y-0.22 Insider Trans0.00% Shs Float31.75M Perf Month-2.20%
Income-18.70M PEG- EPS next Q-0.15 Inst Own33.80% Short Float1.22% Perf Quarter-6.32%
Sales6.90M P/S8.63 EPS this Y-428.30% Inst Trans-9.23% Short Ratio2.23 Perf Half Y-55.28%
Book/sh0.43 P/B4.14 EPS next Y57.70% ROA-66.40% Target Price9.83 Perf Year-35.04%
Cash/sh0.52 P/C3.40 EPS next 5Y- ROE-97.40% 52W Range1.50 - 4.25 Perf YTD4.09%
Dividend- P/FCF- EPS past 5Y-9.00% ROI-103.40% 52W High-58.12% Beta1.27
Dividend %- Quick Ratio3.80 Sales past 5Y-20.10% Gross Margin- 52W Low18.67% ATR0.10
Employees20 Current Ratio3.80 Sales Q/Q1035.20% Oper. Margin- RSI (14)48.44 Volatility6.42% 5.77%
OptionableYes Debt/Eq0.00 EPS Q/Q98.90% Profit Margin- Rel Volume0.52 Prev Close1.75
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 AMC Payout- Avg Volume174.21K Price1.78
Recom1.30 SMA201.19% SMA50-1.01% SMA200-34.16% Volume90,232 Change1.71%
Oct-15-15Initiated FBR Capital Outperform $6
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
May-05-14Initiated MLV & Co Buy $6
Oct-18-13Reiterated Ladenburg Thalmann Buy $5 → $2.75
Oct-08-13Initiated Northland Capital Outperform $7
Apr-10-13Upgrade Ladenburg Thalmann Neutral → Buy $4
Nov-18-09Initiated Ladenburg Thalmann Buy $9
Feb-15-17 01:04PM  PSIVIDA CORP. Financials
Feb-10-17 07:00AM  pSivida to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-09-17 04:18PM  PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report +5.68%
Feb-08-17 04:12PM  PSIVIDA CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits +6.02%
Feb-07-17 09:19PM  Edited Transcript of PSDV earnings conference call or presentation 7-Feb-17 9:30pm GMT
05:30PM  PSivida posts 2Q loss
04:04PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results GlobeNewswire
07:07AM  Q2 2017 pSivida Corp Earnings Release - After Market Close
Jan-25-17 07:00AM  pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Jan-10-17 04:32PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +10.58%
Dec-30-16 08:32AM  PSIVIDA CORP. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal Of
Dec-23-16 12:34PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +7.07%
Dec-20-16 08:35AM  PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-16-16 07:58PM  pSivida Corp. (PSDV): Heres How It Stacks Up Versus Its Peers at Insider Monkey +8.12%
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
Dec-13-16 11:45AM  ETFs with exposure to pSivida Corp. : December 13, 2016 -8.24%
Dec-02-16 01:07PM  ETFs with exposure to pSivida Corp. : December 2, 2016
Nov-10-16 12:56PM  ETFs with exposure to pSivida Corp. : November 10, 2016
Nov-09-16 11:57AM  pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016
Nov-08-16 01:45PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Nov-07-16 10:39PM  Edited Transcript of PSDV earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.61%
05:04PM  PSivida reports 1Q loss
04:15PM  Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development GlobeNewswire
04:07PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline GlobeNewswire
07:07AM  Q1 2017 pSivida Corp Earnings Release - After Market Close
Oct-31-16 07:00AM  pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information GlobeNewswire
Oct-28-16 03:15PM  ETFs with exposure to pSivida Corp. : October 28, 2016
Oct-18-16 10:59AM  ETFs with exposure to pSivida Corp. : October 18, 2016
Oct-17-16 09:16AM  pSivida Corp. :PSDV-US: Earnings Analysis: 2016 By the Numbers : October 17, 2016
Oct-04-16 07:00AM  Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target GlobeNewswire
Oct-03-16 11:18AM  ETFs with exposure to pSivida Corp. : October 3, 2016
Sep-28-16 04:03PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Sep-27-16 07:00AM  pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist GlobeNewswire
Sep-22-16 09:00AM  pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference GlobeNewswire
Sep-20-16 05:17PM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:01PM  pSivida Reports Inducement Awards to New President and Chief Executive Officer GlobeNewswire
Sep-15-16 11:25AM  Watertown's pSivida appoints new CEO to focus on commercialization at bizjournals.com
07:00AM  pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO GlobeNewswire
Sep-13-16 02:30PM  PSIVIDA CORP. Files SEC form 10-K, Annual Report
02:03AM  Edited Transcript of PSDV earnings conference call or presentation 12-Sep-16 8:30pm GMT
Sep-12-16 04:17PM  PSivida reports 4Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results GlobeNewswire
07:07AM  Q4 2016 pSivida Corp Earnings Release - After Market Close
Sep-01-16 10:00AM  pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Aug-29-16 10:00AM  pSivida Announces 13 New Patents Issued or Allowed GlobeNewswire
Aug-15-16 09:00AM  Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting GlobeNewswire
Aug-09-16 10:00AM  Primary Endpoint Met in pSividas Utilization Study of New Medidur Inserter with Smaller Diameter Needle GlobeNewswire
Aug-03-16 08:00AM  pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer GlobeNewswire
Aug-01-16 07:00AM  pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis GlobeNewswire
Jul-27-16 04:25PM  pSivida Corp.: Strong price momentum but will it sustain?
07:30AM  pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) GlobeNewswire
Jul-20-16 12:50PM  ETFs with exposure to pSivida Corp. : July 20, 2016 +5.11%
08:00AM  Data Shows pSividas Tethadur Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy GlobeNewswire
Jul-18-16 04:03PM  PSIVIDA CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financ
Jul-15-16 08:00AM  pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility GlobeNewswire
Jul-14-16 11:00AM  Investigator-Sponsored Phase 2 Study Results Show pSividas Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve GlobeNewswire +7.36%
Jul-08-16 08:29AM  pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting GlobeNewswire
Jul-05-16 08:00AM  pSivida Announces Successful Completion of Two Preclinical Studies of Durasert Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD GlobeNewswire
May-12-16 01:09PM  pSivida Corp. :PSDV-US: Earnings Analysis: Q3, 2016 By the Numbers -5.74%
May-06-16 12:40PM  PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report
May-05-16 06:20PM  PSivida reports 3Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results GlobeNewswire
07:07AM  Q3 2016 pSivida Corp Earnings Release - After Market Close
May-04-16 08:00AM  pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics GlobeNewswire
May-02-16 07:30AM  pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe GlobeNewswire
Apr-27-16 09:00AM  pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Mar-24-16 09:10AM  pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention at noodls
09:00AM  pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention GlobeNewswire
Mar-15-16 10:00AM  Additional Favorable Six-Month Safety Results for pSivida's Medidur for Posterior Uveitis GlobeNewswire
Feb-11-16 10:51AM  pSivida Corp. Earnings Analysis: Q2, 2016 By the Numbers
Feb-09-16 06:05AM  PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers -5.00%
12:01AM  Edited Transcript of PSDV earnings conference call or presentation 8-Feb-16 9:30pm GMT
Feb-08-16 04:30PM  pSivida Corp Earnings Call scheduled for 4:30 pm ET today -5.33%
04:20PM  PSivida reports 2Q loss AP
04:02PM  PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results GlobeNewswire
07:07AM  Q2 2016 pSivida Corp Earnings Release - After Market Close
Feb-01-16 12:52PM  pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information at noodls
12:15PM  pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information GlobeNewswire
Jan-28-16 11:05AM  pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 at noodls
10:30AM  pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 GlobeNewswire
Jan-13-16 07:45AM  pSivida Closes $17.8 Million Offering GlobeNewswire -5.08%
Jan-08-16 05:30PM  PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -8.55%
Jan-07-16 08:21AM  pSivida Announces Pricing of $16 Million Public Offering of Common Stock GlobeNewswire
Jan-06-16 05:57PM  pSivida Announces Proposed Public Offering of Common Stock GlobeNewswire -7.81%
Dec-28-15 12:04PM  pSivida shares hit new high on plans to file for European drug approval at bizjournals.com +8.47%
07:15AM  pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial GlobeNewswire
04:15AM  Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp.
Dec-23-15 05:15PM  pSivida Corp.: Strong price momentum but will it sustain?
12:42PM  pSivida Corp. Earnings Analysis: Q1, 2016 By the Numbers
Dec-22-15 01:03PM  What Is Driving These Stocks Gains Today? at Insider Monkey +21.35%
12:25PM  PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11:50AM  4 Stocks to Watch Trading Under $500M Market Cap Accesswire
11:45AM  pSivida Soars on Positive Late Stage Results
10:30AM  Why pSivida And Alexza Are Skyrocketing
07:15AM  PSivida Corp says experimental eye drug meets study goal
pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashton PaulPresident & CEOMar 18Option Exercise1.1310,00011,300450,741Mar 22 12:24 PM